You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Respiratory conditions
  5. Asthma

Benralizumab for treating severe eosinophilic asthma

  • Technology appraisal guidance
  • Reference number: TA565
  • Published:  06 March 2019
  • Last updated:  03 September 2019
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download (PDF)

Resource impact information

A new resource impact template and statement for people with severe eosinophilic asthma has been published. This can be used to model the potential resource impact associated with this technology.

This page was last updated: 03 February 2021

Back to top